The new framework agreement means their use will be extended in line with the NHS`s long-term plan to tackle stroke and other cardiovascular diseases. NHS Framework Agreement for the supply of direct oral anticoagulants (DOAC) for the NHS in England. Also known as new oral anticoagulants (NOACs). Framework period: 01/11/2021 – 31/04/2024 with the possibility of extending (at the discretion of the Authority) for one or more additional periods up to a total duration of 12 months (i.e. a total possible framework period of 41 months). All documents can be found under health.atamis.co.uk/. Atamis Reference Number: C40079 Title: NHS Framework Agreement for the Supply of Direct Oral Anticoagulant (DOAC) Medicines for the NHS in England Published by: The NHS Commissioning Board (operating as NHS England) Publication date: 23/07/2021 Deadline: 03/09/2021 Deadline: 13:00 Type of notice: The contract notice has documents: None has ESPD: No summary: NHS Framework Agreement for the delivery of direct oral anticoagulants (DOAC) for the NHS in England. Also known as new oral anticoagulants (NOACs). Framework period: 01/11/2021 – 31/04/2024 with the possibility of extending (at the discretion of the Authority) for one or more additional periods up to a total duration of 12 months (i.e. a total possible framework period of 41 months).
All documents can be found under health.atamis.co.uk/. Atamis Reference Number: C40079 Estimated Total Value: Value excluding VAT: GBP 3 185 000 000.00 This trade agreement for DOACs operating from 1. The entry into force in January 2022 builds on NHS England`s approach to eliminating hepatitis C, which included a unique agreement with the pharmaceutical industry to support wider use of hepatitis C treatments for patients who are not yet receiving treatment. He added that although Boehringer Ingelheim – which makes dabigatran – is not involved in the executives, its DOAC will remain an option available to NHS clinicians. Helen Williams, NHS England`s National Specialist for Cardiovascular Disease Prevention, said: “The new agreement for these drugs is good news for the estimated 1.5 million people in England with atrial fibrillation, an irregular heartbeat that causes one in five strokes. Our framework agreements are designed to ensure competitive prices, save money and improve efficiency. To allow for more flexibility, customers have the option to cancel directly from a framework or run a mini-contest. The frames offer a compliant path to the market, offer a comprehensive selection of suppliers and excellent geographical coverage. Frameworks are easy to access and use. If you have any questions about our framework agreements, including the acquisition of an NHS SBS framework provider, please see our Nhs England Framework FAQ The new agreement will make DOACs more affordable and allow the local NHS to provide them to an additional 610,000 patients. The inclusion of DOAC treatment at this level will help prevent approximately 21,700 stokes and save the lives of 5,400 patients from a fatal outcome over the next three years. Depending on your needs, we can arrange one-time access to certain framework agreements to meet a specific need.
Alternatively, we can give you access to our entire portfolio of framework agreements, allowing you to move from a simple purchase to the lowest price based on total cost of ownership to procurement. No matter what procurement support you need, we have flexible options for you. The DOAC deal comes after NICE recommended the drugs as more effective at preventing VORHOFFL-related strokes than other anticoagulants. Download our complete portfolio of framework contracts [218 KB], browse our categories of framework contracts below or search for the framework agreement adapted to your needs via our search engine, which can also be found below. All our clients can access all framework contracts managed by NHS SBS through our online portal, making it faster and easier for you to get the information you need. After a short registration process, you can:¢ view and browse the list of frames (using keywords including supplier names) ⢠View and download flyers, buyer`s guides and other related documents Frame period: 01/11/2021 – 31/04/2024 with the possibility (at the discretion of the authority) to add another period (or periods) up to a total amount of 12 months (i.e. a possible total duration of 41 months) Helen Williams, a consultant pharmacist for cardiovascular disease (CVD) at the South East London Clinical Commissioning Group and National CvD Prevention Advisor at NHS England, described the new deal as “good news” for the 1.5 million AF patients in England. NHS England confirmed to the Pharmaceutical Journal that it has signed agreements on behalf of the BMS/Pfizer alliance with manufacturers Daiichi Sankyo, Bayer and Bristol Myers Squibb (BMS) covering apixaban, edoxaban and rivaroxaban. Speaking at the NHS Suppliers Conference, NHS Chief Executive Amanda Pritchard said: “The measures taken by NHS England will save thousands of lives and prevent many more people from suffering the debilitating effects of stroke by providing this treatment to hundreds of thousands of patients. In addition to expanding the use of direct oral anticoagulants, NHSX also uses cutting-edge technology to diagnose people with life-threatening heart disease, the NHS chief told the NHS Providers conference. Our extensive portfolio of framework agreements is designed for easy access. They provide a compliant market pathway for the NHS and public sector organisations.
We manage £1 billion in spending per year through our framework agreements and can achieve typical savings of around 15%. Nhs England said 20,000 strokes and 5,000 deaths could be prevented as plans to increase the use of direct oral anticoagulants (DOACs) over the next three years. In its statement of 16 November 2021, NHS England said that extending the use of DOAC to 610,000 patients “will help prevent around 21,700 stokes and save the lives of 5,400 patients from a fatal outcome over the next three years”. Paul Wright, Senior Cardiac Pharmacist for barts Heart Centre at Barts Health NHS Trust, said the announcement was “certainly good news”: “There has been a lot of work across the UK to improve the optimisation of anticoagulation for people diagnosed with atrial fibrillation. The technology mentioned to improve diagnosis is also exciting news, because after identification, appropriate anticoagulation can be discussed and, if necessary, initiated.. .